{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:06:20Z","timestamp":1792073180699,"version":"4.4.0"},"reference-count":14,"publisher":"Pharmaceutical Society of Japan","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2022,11,1]]},"DOI":"10.1248\/bpb.b22-00506","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T22:11:42Z","timestamp":1667254302000},"page":"1725-1727","source":"Crossref","is-referenced-by-count":5,"title":["Detection of Characteristic Phosphatidylcholine Containing Very Long Chain Fatty Acids in Cerebrospinal Fluid from Patients with X-Linked Adrenoleukodystrophy"],"prefix":"10.1248","volume":"45","author":[{"given":"Naoki","family":"Fujitani","sequence":"first","affiliation":[{"name":"Sohyaku, Innovative Research Division, Research Unit\/Neuroscience, Mitsubishi Tanabe Pharma Corporation"},{"name":"Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Saito","sequence":"additional","affiliation":[{"name":"Sohyaku, Innovative Research Division, Drug Metabolism and Pharmacokinetics (DMPK) Research Laboratories, Mitsubishi Tanabe Pharma Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Akashi","sequence":"additional","affiliation":[{"name":"Sohyaku, Innovative Research Division, Drug Metabolism and Pharmacokinetics (DMPK) Research Laboratories, Mitsubishi Tanabe Pharma Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Morita","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"So","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Oka","sequence":"additional","affiliation":[{"name":"Sohyaku, Innovative Research Division, Research Unit\/Neuroscience, Mitsubishi Tanabe Pharma Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Bezman L, Moser HW. Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes. Am. J. Med. Genet.<\/i>, 76<\/b>, 415\u2013419 (1998).","DOI":"10.1002\/(SICI)1096-8628(19980413)76:5<415::AID-AJMG9>3.0.CO;2-L"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Engelen M, Kemp S, de Visser M, van Geel BM, Wanders RJ, Aubourg P, Poll-The BT. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J. Rare Dis.<\/i>, 7<\/b>, 51 (2012).","DOI":"10.1186\/1750-1172-7-51"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Moser HW. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain<\/i>, 120<\/b>, 1485\u20131508 (1997).","DOI":"10.1093\/brain\/120.8.1485"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Vogel BH, Bradley SE, Adams DJ, D\u2019Aco K, Erbe RW, Fong C, Iglesias A, Kronn D, Levy P, Morrissey M, Orsini J, Parton P, Pellegrino J, Saavedra-Matiz CA, Shur N, Wasserstein M, Raymond GV, Caggana M. Newborn screening for X-linked adrenoleukodystrophy in New York State: diagnostic protocol, surveillance protocol and treatment guidelines. Mol. Genet. Metab.<\/i>, 114<\/b>, 599\u2013603 (2015).","DOI":"10.1016\/j.ymgme.2015.02.002"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Rasmussen M, Moser AB, Borel J, Khangoora S, Moser HW. Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo\u2019s oil). Neurochem. Res.<\/i>, 19<\/b>, 1073\u20131082 (1994).","DOI":"10.1007\/BF00968719"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Lund TC, Stadem PS, Panoskaltsis-Mortari A, Raymond G, Miller WP, Tolar J, Orchard PJ. Elevated cerebral spinal fluid cytokine levels in boys with cerebral adrenoleukodystrophy correlates with MRI severity. PLOS ONE<\/i>, 7<\/b>, e32218 (2012).","DOI":"10.1371\/journal.pone.0032218"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Engelen M, Kemp S, Poll-The BT. X-linked adrenoleukodystrophy: pathogenesis and treatment. Curr. Neurol. Neurosci. Rep.<\/i>, 14<\/b>, 486 (2014).","DOI":"10.1007\/s11910-014-0486-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Theda C, Moser AB, Powers JM, Moser HW. Phospholipids in X-linked adrenoleukodystrophy white matter: fatty acid abnormalities before the onset of demyelination. J. Neurol. Sci.<\/i>, 110<\/b>, 195\u2013204 (1992).","DOI":"10.1016\/0022-510X(92)90028-J"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Hama K, Fujiwara Y, Morita M, Yamazaki F, Nakashima Y, Takei S, Takashima S, Setou M, Shimozawa N, Imanaka T, Yokoyama K. Profiling and imaging of phospholipids in brains of abcd1-deficient mice. Lipids<\/i>, 53<\/b>, 85\u2013102 (2018).","DOI":"10.1002\/lipd.12022"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Eichler FS, Ren JQ, Cossoy M, Rietsch AM, Nagpal S, Moser AB, Frosch MP, Ransohoff RM. Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy? Ann. Neurol.<\/i>, 63<\/b>, 729\u2013742 (2008).","DOI":"10.1002\/ana.21391"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Morita M, Imanaka T. Peroxisomal ABC transporters: structure, function and role in disease. Biochim. Biophys. Acta BBAMol. Basis Dis.<\/i>, 1822<\/b>, 1387\u20131396 (2012).","DOI":"10.1016\/j.bbadis.2012.02.009"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Igarashi M, Schaumburg HH, Powers J, Kishimoto Y, Koilodny E, Suzuki K. Fatty acid abnormality in adrenoleukodystrophy. J. Neurochem.<\/i>, 26<\/b>, 851\u2013860 (1976).","DOI":"10.1111\/j.1471-4159.1976.tb04462.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Wilson R, Sargent JR. Lipid and fatty acid composition of brain tissue from adrenoleukodystrophy patients. J. Neurochem.<\/i>, 61<\/b>, 290\u2013297 (1993).","DOI":"10.1111\/j.1471-4159.1993.tb03567.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Richmond PA, van der Kloet F, Vaz FM, Lin D, Uzozie A, Graham E, Kobor M, Mostafavi S, Moerland PD, Lange PF, van Kampen AHC, Wasserman WW, Engelen M, Kemp S, van Karnebeek CDM. Multi-omic approach to identify phenotypic modifiers underlying cerebral demyelination in X-linked adrenoleukodystrophy. Front. Cell Dev. Biol.<\/i>, 8<\/b>, 520 (2020).","DOI":"10.3389\/fcell.2020.00520"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/45\/11\/45_b22-00506\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:50:41Z","timestamp":1715316641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/45\/11\/45_b22-00506\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b22-00506","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]},"article-number":"b22-00506"}}